Acta Diabetologica最新文献

Purpose: Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and basal insulin are currently used in the treatment of type 2 diabetes mellitus (T2DM) as long-acting injectables. In this study, we aimed to compare the cardiovascular (CV) and renal outcomes of GLP-1 RAs and basal insulin treatment in patients with T2DM.

Method: We conducted a propensity score-matched cohort study of patients from Chang Gung Memorial Hospital institutions between 2013 and 2021. A diverse patient base from multiple centers was enrolled to enhance the applicability of the findings, including patients with T2DM who were prescribed either GLP-1 RAs or basal insulin.

Results: Over a mean follow-up period of 2.2 years, 10,839 patients were collected (mean age = 54.3 years; 54.2% men). Among the propensity score-matched patients, 45 (2.23%) in the GLP-1 RA group (2,854 patients) and 72 (3.56%) in the basal insulin group (7,985 patients) experienced 3-point major adverse cardiovascular events (3P-MACEs; hazard ratio [HR] 0.68, 95% CI 0.47-0.99, P =.44). Additionally, composite renal outcomes were observed in 237 (11.7%) patients in the GLP-1 RA group and 360 (17.8%) in the basal insulin group (HR 0.69, 95% CI 0.59-0.81, P <.001).

Conclusions: In patients with T2DM, GLP-1 RAs were associated with more favorable cardiovascular and renal outcomes than basal insulin, suggesting that GLP-1 RA treatment may be a preferable option for managing T2DM with a lower risk of CV and renal complications.

Objective: The objective is to investigate the differences in urinary organic acid (OA) profiles and metabolism between healthy control (HC) pregnant women and those with gestational diabetes mellitus (GDM) during the second trimester and third trimester of pregnancy.

Methods: A total of 66 HC pregnant women and 32 pregnant women with GDM were assessed for 107 hydrophilic metabolites in urine samples collected during the second and third trimester of pregnancy using tandem mass spectrometry. The urine OA profiles for each group were obtained, and metabolomic analysis and discussion were conducted.

Results: This study identified a total of 50 metabolic biomarkers. In the third trimester of pregnancy, short-chain dicarboxylic acids (DCAs) and tryptophan (Trp)-related metabolites were significantly upregulated in the urine of both the HC group and the GDM group. Comparatively, the glycine (Gly) levels and related synthetic precursor metabolites were lower in the GDM2 group. The overall dietary polyphenol metabolic intermediates level in the GDM group was lower than in the HC group. Among the pathways enriched for differentially expressed metabolites, the predominant metabolic pathway in the GDM group was the citric acid cycle. In contrast, in the HC group, it was the metabolism of alanine, aspartate, and glutamate.

Conclusions: The study reveals the differences in metabolomics between pregnant women with HC and those with GDM, identifying several metabolites associated with the occurrence and development of GDM. Demonstrating the presence of abnormal mitochondrial and peroxisomal functions at the metabolite level in GDM will contribute to future exploration of the condition.

Background: Evidence suggests a bidirectional relationship between oral health status and type 2 diabetes (T2D) in adults. Studies on associations between childhood oral health and T2D in adulthood are lacking.

Methods: This is a nationwide Danish registry-based cohort study of individuals born between 1963 and 1972, having at least one registration in the National Child Odontology Registry between 1972 and 1987 (n = 627,758). Follow-up lasted from 1995 to 2018. Main exposure variables were the highest achieved levels of dental caries and gingivitis between 1972 and 1987. The outcome was T2D diagnosis during follow-up. Data was analyzed using Cox-regression, stratified on sex, with age as the underlying timescale and highest achieved level of education between age 25-30 years as Cox-strata. Main analyses were conducted with and without age-restrictions (T2D diagnosis before/after age 40).

Results: Compared to lowest-level references, high levels of gingivitis associated with increased hazard ratios (HRs) of T2D in both males (HR [95% confidence interval]: 1.59 [1.47; 1.72]) and females (1.87 [1.68; 2.08]), as did severe dental caries (males: (1.15 [1.04; 1.27], in females: 1.19 [1.06; 1.35]). Below age 40, gingivitis associated with increased HRs in males (1.84 ([1.58; 2.15]) and females (1.94 [1.63; 2.30]). Above age 40, both exposures displayed higher HRs in males (high gingivitis: 1.52 [1.39; 1.66] vs. severe caries: 1.23 [1.09; 1.38]) and females (1.83 [1.59; 2.10] vs. 1.37 [1.17; 1.59]).

Conclusions: Data suggest an association between childhood dental caries and gingivitis with risk of receiving a T2D diagnosis in adulthood. However, results are affected by residual confounding warranting further studies.

Aims: To assess the efficacy and safety of automated insulin delivery (AID) systems compared to standard care in managing glycaemic control during pregnancy in women with Type 1 Diabetes Mellitus (T1DM).

Methods: We searched MEDLINE, Cochrane Library, registries and conference abstracts up to June 2024 for randomized controlled trials (RCTs) and observational studies comparing AID to standard care in pregnant women with T1DM. We conducted random effects meta-analyses for % of 24-h time in range of 63-140 mg/dL (TIR), time in hyperglycaemia (> 140 mg/dl and > 180 mg/dL), hypoglycaemia (< 63 mg/dl and < 54 mg/dL), total insulin dose (units/kg/day), glycemic variability (%), changes in HbA1c (%), maternal and fetal outcomes.

Results: Thirteen studies (450 participants) were included. AID significantly increased TIR (Mean difference, MD 7.01%, 95% CI 3.72-10.30) and reduced time in hyperglycaemia > 140 mg/dL and > 180 mg/dL (MD - 5.09%, 95% CI - 9.41 to - 0.78 and MD - 2.44%, 95% CI - 4.69 to - 0.20, respectively). Additionally, glycaemic variability was significantly reduced (MD - 1.66%, 95% CI - 2.73 to - 0.58). Other outcomes did not differ significantly.

Conclusion: AID systems effectively improve glycaemic control during pregnancy in women with T1DM by increasing TIR and reducing hyperglycaemia without any observed adverse short-term effects on maternal and fetal outcomes.

Background: Visceral adipose tissue (VAT) is known to play a role in the development of metabolic and cardiovascular disease (CVD). However, the age- and sex-specific associations between VAT and these diseases remain unclear.

Methods: In this cross-sectional study, 1,150 participants (39.5% women; mean age 61.5 years) underwent VAT measurement using dual abdominal bioelectrical impedance analysis (BIA). The four age groups that the participants were divided into were 18-44, 45-59, 60-74, and ≥ 75 years. The relationships between VAT and cardiometabolic outcomes were analyzed by age and sex using multivariable logistic regression.

Results: Significant associations between VAT and metabolic health status were observed in middle-aged (45-59 years; OR = 1.41, 95% CI: 1.04-1.92) and elderly adults (60-74 years; OR = 1.45, 95% CI: 1.10-1.92). VAT demonstrated age-dependent relationships with cardiovascular risk factors, with the strongest associations found in the 60-74 years group for hypertension (OR: 1.55, 95% CI: 1.22-1.98) and low high-density lipoprotein cholesterol (OR: 1.66, 95% CI: 1.33-2.08). Notably, the VAT-CVD association was most pronounced in elderly women (60-74 years; OR: 1.86, 95% CI: 1.14-3.11), while no significant associations were observed in men across all age groups.

Conclusions: The impact of VAT on metabolic and cardiovascular disease risk varies by age and sex, with particularly strong associations observed in elderly women. This highlights the need for tailored prevention and treatment strategies.

Background: To investigate the association of frailty status and its changes with new-onset diabetes.

Methods: A total of 4638 participants from the China Health and Retirement Longitudinal Study (CHARLS) were included. Frailty status was assessed by the frailty index (FI) and categorized as robust, pre-frail, and frail. Changes in frailty were assessed based on frailty status at wave1 and wave3 of CHARLS. New-onset diabetes was identified by self-reported physician-diagnosed or diagnosed by glucose or glycosylated haemoglobin during follow-up period. Logistic regression was used to examine the association of frailty and outcomes.

Results: 51.6%, 38.1% and 10.3% of the individuals were respectively classified as robust, pre-frail, and frail at baseline. The risk of new-onset diabetes was significantly higher in the pre-frailty [odds ratio (OR) (95% confidence interval (CI)): 1.326 (1.101-1.597), p = 0.003)] and frailty [OR(95% CI): 1.721 (1.304-2.271), p < 0.001)] than the robust. A total of 3145 participants were included in the changes of frailty status analyses. Compared with the stable robust individuals, individuals who developed from robust to frailty status [OR (95%CI): 3.752 (1.647-8.547), p = 0.002] had an elevated risk of new-onset diabetes. In addition, participants who ever had a robust status in the two surveys had a significantly lower risk of new-onset diabetes compared to those who never had a robust status [OR (95%CI) 0.666 (0.483-0.920), p = 0.014)].

Conclusion: Frailty status is significantly associated with the risk of new-onset diabetes. The progression from robust to frailty or pre-frailty increased the risk of new-onset diabetes.

Aims: This review examines the challenges posed by Diabetic Foot Infections (DFIs), focusing on the impact of neuropathy, peripheral arterial disease, immunopathy, and the polymicrobial nature of these infections. The aim is to explore the factors contributing to antimicrobial resistance and assess the potential of novel antimicrobial treatments and drug delivery systems in improving patient outcomes.

Method: A comprehensive analysis of existing literature on DFIs was conducted, highlighting the multifactorial pathogenesis and polymicrobial composition of these infections. The review delves into the rise of antimicrobial resistance due to the overuse of antimicrobials, biofilm formation, and microbial genetic adaptability. Additionally, it considers glycemic control, patient adherence, and recurrence rates as contributing factors to treatment failure. Emerging therapies, including new antimicrobial classes and innovative drug delivery systems, were evaluated for their potential efficacy.

Results: DFIs present unique treatment challenges, with high rates of antimicrobial resistance and poor response to standard therapies. Biofilm formation and the genetic adaptability of pathogens worsen resistance, complicating treatment. Current antimicrobial therapies are further hindered by poor glycemic control and patient adherence, leading to recurrent infections. Novel antimicrobial classes and innovative delivery systems show promise in addressing these challenges by offering more targeted, effective treatments. These new approaches aim to reduce resistance and improve treatment outcomes.

Conclusion: DFIs remain a clinical challenge due to their multifactorial nature and antimicrobial resistance. The development of novel antimicrobials and drug delivery systems is crucial to improving patient outcomes and combating resistance. Future research should focus on enhancing treatment efficacy, reducing resistance, and addressing patient adherence to reduce the burden of DFIs.

Aims: This study aims to evaluate the impact of continuous glucose monitoring (CGM) on pregnancy outcomes in women with pregestational diabetes mellitus (PGDM).

Methods: A retrospective cohort study was conducted on 387 pregnant women with PGDM at Virgen del Rocío University Hospital in Seville, spanning from 2016 to 2022. The patients were categorized into two groups: 212 women who used continuous glucose monitoring (CGM) and 175 women who self-monitoring of blood glucose (SMBG). The study evaluated maternal characteristics, pregnancy complications, delivery methods, neonatal outcomes, and congenital anomalies.

Results: The CGM group exhibited lower weight gain during pregnancy (9.6 kg vs. 10.0 kg, p = 0.02) and required fewer prenatal visits (7 vs. 8, p = 0.01). The rate of cesarean sections was significantly lower in the CGM group (53.1% vs. 58.2%, p = 0.03), and the incidence of macrosomia was reduced (12.9% vs. 22.2%, p = 0.04). There were no significant differences in congenital anomalies, intrauterine fetal deaths, or neonatal deaths between the groups.

Conclusions: CGM in pregnant women with PGDM is associated with better pregnancy outcomes, including reduced cesarean section rates and lower incidence of macrosomia. These findings support the wider implementation of CGM for improved maternal and fetal health in PGDM pregnancies.

Introduction: Skeletal muscle is the largest insulin-sensitive tissue in the human body, alteration in muscle mass and strength substantially impact glucose metabolism. This systematic review aims to investigate further the relationship between muscle mass and strength towards type 2 diabetes mellitus (T2DM) incidence.

Methods: This systematic review included cohort studies that examinedthe relationship between muscle mass and/or muscle strength on T2DM incidence. A comprehensive search was conducted across PubMed, EBSCO, ProQuest, and Google scholar employing specific Medical Subject Headings (MeSH) and relevant keywords related to or synonymous with "muscle mass", "muscle strength", and "Type 2 Diabetes Mellitus incidence".

Results: Twenty-five cohort studies were included, 11 studies on muscle mass and 16 studies on muscle strength. Participants included were 278,475 for muscle mass and 400,181 for muscle strength. Skeletal muscle mass normalized to body weight (SMM/BW), appendicular skeletal musce mass normalized to body weight (ASM/BW), and handgrip strength normalized to body mass index (HGS/BMI) consistently demonstrate significant inverse association with T2DM even after sex and/or BMI stratification. Handgrip strength normalized to body weight (HGS/BW) demonstrates a strong inverse association with T2DM incidence, however, adiposity should be considered.

Conclusion: Muscle mass and strength demonstrate strong association with T2DM incidence. Adiposity, a key T2DM risk factor, should also be assessed through a simple BMI or a sophisticated technique with BIA or CT-scan. The combination of muscle variables and adiposity could further enhance T2DM risk assessment. However, T2DM risks are multifactorial, with various contributing factors, further large-scale studies are needed to validate these findings.